FOLH1 and metastatic prostate carcinoma: Plasma extracellular vesicle proteomics nominates candidate biomarkers of &lt;sup&gt;177&lt;/sup&gt;Lu-PSMA-617 outcomes in metastatic prostate cancer patients.